Tables e1a-d. Diagnostic and drug codes for the identification of the multiple sclerosis population, DMT exposures, and study outcomes
|
|
- Kory Joseph
- 5 years ago
- Views:
Transcription
1 Appendix
2 Tables e1a-d. Diagnostic and drug codes for the identification of the multiple sclerosis population, DMT exposures, and study outcomes Table e-1a Multiple sclerosis and demyelinating disease related codes and drug identification numbers of the disease-modifying therapies ICD-9 1 ICD-10 Drug identification number Multiple sclerosis Multiple sclerosis 340 G35 Demyelinating disease Optic neuritis H46 Acute transverse myelitis G Acute disseminated 323 G36.9 encephalomyelitis Demyelinating disease of CNS G37.8 unspecified Other acute disseminated G36 demyelination Neuromyelitis optica G36.0 Disease-modifying therapy Betaseron (IFNB-1b) Extavia (IFNB-1b) Avonex (IFNB-1a) Rebif (IFNB-1a) Copaxone (glatiramer acetate) Tysabri (natalizumab) Gilenya (fingolimod) Tecfidera (dimethyl fumarate) Aubagio (teriflunomide) Lemtrada (alemtuzumab) Key: The DMTs listed represented all those available (approved) for use in MS by Health Canada at some point during the study
3 Table e-1b ICD-9-CM and ICD-10-CA codes for identification of infection-related physician claims and hospital admissions Infection ICD-9 ICD-10 Intestinal infectious diseases 001.xx 009.xx A00.xx -A09.xx Tuberculosis 010.xx 018.xx A15.xx -A19.xx Zoonotic bacterial diseases 020.xx 027.xx A20.xx -A28.xx Other bacterial disease (eg. leprosy, diseases due to 030.xx 041.xx A30.xx -A49.xx other mycobacteria, diphtheria, whooping cough, septicemia) Human immunodeficiency virus 042.xx B20.xx Poliomyelitis and other non-arthropod-borne viral 045.xx 049.xx A80.xx -A81.xx, disease of central nervous system Viral diseases accompanied by exanthem (eg. smallpox; cowpox and paravaccinia, chickenpox, herpes zoster, herpes simplex, measles, rubella) 050.xx -059.xx A85.xx -A89.xx B00.xx -B09.xx Arthropod-borne viral diseases 060.xx 066.xx A83.xx -A85.xx, A90.xx -A99.xx Other disease due to viruses and chlamydiae 070.xx 079.xx B15.xx -B19.xx, A70.xx -A74.xx, A82.xx, B25.xx -B34.xx, B07.xx Rickettsioses and other arthropod-borne disease 080.xx 088.xx A75.xx -A79.xx, B50.xx -B57.xx Syphilis and other venereal diseases 090.xx 099.xx A50.xx -A64.xx Other spirochetal diseases 100.xx 104.xx A65.xx -A69.xx Mycoses 110.xx 118.xx B35.xx -B49.xx Helminthiasis 120.xx 129.xx B65.xx -B83.xx Other infections and parasitic diseases 130.xx 136.xx B58.xx -B64.xx, B85.xx -B89.xx Late effects of infectious and parasitic diseases 137.xx 139.xx B90.xx -B94.xx Bacterial meningitis 320.xx G00.xx, G01.xx, G04.2x Meningitis due to other organisms 321.xx B45.1x, G02.xx, Meningitis of unspecified cause 322.xx G03.0x G03.8x, G03.1x, G03.9x Intracranial and intraspinal abscess 324.xx G06.xx Late effects of intracranial abscess or pyogenic 326.xx G09.xx infection Blepharitis 373.0x H01.0x Infective dermatitis of eyelid of types resulting in 373.4x H01.8x deformity Other infective dermatitis of eyelid 373.5x H01.8x Parasitic infection of eyelid 373.6x B89.xx Acute inflammation of orbit 376.0x H05.0x
4 Table e-1b ICD-9-CM and ICD-10-CA codes for identification of infection-related physician claims and hospital admissions (continued) Infection ICD-9 ICD-10 Infective otitis externa 380.1x H60.0x, H60.1x, H60.2x, H60.3x, H62.4x Suppurative and unspecified otitis media 382.xx H66.xx Acute mastoiditis 383.0x H70.0x Acute nasopharyngitis (common cold) 460.xx J00.xx Acute sinusitis 461.xx J01.xx Acute pharyngitis 462.xx J02.xx Acute tonsillitis 463.xx J03.xx Acute laryngitis and tracheitis 464.xx J04.xx, J05.xx Acute upper respiratory tract infection of multiple or 465.xx J06.xx unspecified sites Acute bronchitis and bronchiolitis 466.xx J20.xx, J21.xx Chronic sinusitis 473.xx J32.xx Chronic disease of tonsils and adenoids 474.xx J35.xx Chronic laryngitis and laryngotracheitis 476.xx J37.xx Viral pneumonia 480.xx J12.xx Pneumococcal pneumonia 481.xx J13.xx, J18.1x Other bacterial pneumonia 482.xx J15x, J14x Pneumonia due to other specified organism 483.xx J16.xx Pneumonia in infectious diseases classified elsewhere 484.xx J17.xx Bronchopneumonia, organism unspecified 485.xx J18.0x Pneumonia, organism unspecified 486.xx J18.xx Influenza 487.xx J11.xx, J10.xx, J09.xx Bronchitis, not specified as acute or chronic 490.xx J40.xx Infections of the kidney 590.xx N10.xx, N11. xx, N12.xx,, N15.1x, N28.84, N28.85, N28.86, N16.xx Cystitis 595.xx N30.xx Urethritis not sexually transmitted 597.xx N34.xx Urinary tract infection, site not specified 599.0x N39.0x Inflammatory disease of prostate (prostatitis) 601.xx N41.xx Carbuncle and furuncle 680.xx L02.xx Cellulitis and abscess of finger and toe 681.xx L03.xx Other cellulitis and abscess 682.xx L03.xx Acute lymphadenitis 683.xx L04.xx Impetigo 684.xx L01.xx Other local infections of skin and subcutaneous tissue 686.xx L08.xx, L88.xx, L98.0x, Septic arthritis 711.0x M00.xx, M01.xx
5 Table e-1b ICD-9-CM and ICD-10-CA codes for identification of infection-related physician claims and hospital admissions (continued) Infection ICD-9 ICD-10 Osteomyelitis periostitis and other infections involving bone 730.xx M86.xx, M46.2x M46.3x, M89.6x Bacteremia 790.7x R78.81 Viremia 790.8x B34.9x Key: ICD-9-CM=International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CA= International Classification of Diseases, Tenth Revision, Canada. ICD10 was only used to identify infection -related hospitalizations.
6 Table e-1c ICD-9-CM and ICD-10-CA codes for identification of the five most common infection groups Infection type ICD-9 ICD-10 Upper respiratory tract infections xx-465.xx J00.xx- J06.xx Infections of urinary system xx; 590.xx; 597.xx; 599.0x N10.xx, N11.xx, N12.xx,, N15.1x, N16.xx. N28.84, N28.85, N28.86, N30.xx, N34.xx, N39.0x, Bronchitis and bronchiolitis xx; 490.xx J20.xx, J21.xx, J40.xx Infections of the skin and subcutaneous tissue 680.xx-686.xx L01.xx-L08.xx, L88.xx, L98.0x Pneumonia xx 486.xx J12.xx- J18.xx Key: ICD-9-CM=International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CA= International Classification of Diseases, Tenth Revision, Canada. ICD-10 was only used to identify infection-related hospitalizations. Groups were created based on prior literature (as shown) or by combining related ICD sub-chapters (e.g. as for infections of the skin and subcutaneous tissue) Source references 1. Mueller EL, Walkovich KJ, Mody R, Gebremariam A and Davis MM. Hospital discharges for fever and neutropenia in pediatric cancer patients: United States, BMC Cancer. 2015; 15: Nelson RE, Xie Y, DuVall SL, et al. Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans. Int J MS Care. 2015; 17: Chang LY, Lai CC, Chen CJ, et al. Recent trends in prescribing antibiotics for acute tonsillitis in pediatric ambulatory care in Taiwan, : A nationwide population-based study. J Microbiol Immunol Infect. 2015: Wang EE, Einarson TR, Kellner JD and Conly JM. Antibiotic prescribing for Canadian preschool children: evidence of overprescribing for viral respiratory infections. Clin Infect Dis. 1999; 29:
7 Table e-1d The first and second generation disease modifying drugs for MS approved in Canada by the end of 2013 Health Canada Approval data Generation Date of first prescription filled in the current study Betaseron (IFNB-1b) July 1995 first July 1996 Extavia (IFNB-1b) January 2010 first N/A Avonex (IFNB-1a) April 1998 first October 1998 Rebif (IFNB-1a) February 1998 first June 1998 Copaxone (glatiramer October 1997 first February 1998 acetate) Tysabri (natalizumab) October 2006 second March 2007 Gilenya (fingolimod) March 2011 second July 2011 Tecfidera (dimethyl fumarate) Aubagio (teriflunomide) Lemtrada (alemtuzumab) April 2013 second June 2013 November 2013 second N/A December 2013 second N/A Key: N/A = not applicable; no individual filled a prescription for this DMT during the study All approval dates were obtained from Health Canada (available at:
8 Table e-1e ICD-9-CM and ICD-10-CA codes for identification of comorbidities in the multiple sclerosis population Comorbidity ICD-9 ICD-10 Diabetes 250.xx E10.xx -E14.xx Malignancies 140.xx-209.xx 235.xx-239.xx C00.xx-C96.xx D37.xx-D49.xx Rheumatoid arthritis 714.xx M05.xx -M06.xx Psoriasis 696.0x, 696.1x L40.xx, M07.0x- M07.3x Inflammatory bowel disease 555.xx, 556.xx K50.xx, K51.xx Chronic lung disease 493.xx, 491.xx, 492.xx, 496.xx J45.xx, J46.xx, J40.xx, J42.xx, J43.xx, J44.xx Key: ICD-9-CM=International Classification of Diseases, Ninth Revision, Clinical Modification; ICD-10-CA= International Classification of Diseases, Tenth Revision, Canada. Comorbidities were identified using health administrative data ( 1 hospital admission or 2 physician claims for the relevant diagnostic code) based on data in the 5 years prior to the index date (for pre-index date comorbidities) as well as over the entire study period. Once a comorbidity was identified, an individual was considered affected from the date of the first relevant claim and thereafter. ICD-10 was only used to identify hospitalizations.
9 Table e-2 Characteristics of the multiple sclerosis study population at the index date by subsequent disease-modifying treatment exposure Characteristics Unexposed 1 DMT Any betainterferon Glatiramer acetate Natalizumab Any oral DMT 1 st and 2 nd 1 st generation 1 st generation 2 nd generation 2 nd generation generation combined N=5077 N=1716 N=1386 N=656 N=100 N=98 Age (yrs), mean (SD) 47.8 (13.5) 38.2 (9.4) 38.0 (9.4) 37.7 (9.2) 34.5 (9.6) 35.3 (9.1) Women, N (%) 3712 (73.1) 1287 (75.0) 1039 (75.0) 500 (76.2) 71 (71.0) 76 (77.6) Index year, N (%) (35.0) 642 (37.4) 569 (41.1) 189 (28.8) 23 (23.0) 12 (12.2) (36.6) 659 (38.4) 541 (39.0) 278 (42.4) 60 (60.0) 38 (38.8) (28.4) 415 (24.2) 276 (19.9) 189 (28.8) 17 (17.0) 48 (49.0) SES, N (%) 1 (lowest income quintile) 891 (17.5) 308 (17.9) 253 (18.3) 126 (19.2) 19 (19.0) 13 (13.3) (19.4) 319 (18.6) 257 (18.5) 118 (18.0) 18 (18.0) 18 (18.4) (20.7) 359 (20.9) 296 (21.4) 142 (21.6) 19 (19.0) 19 (19.4) (21.6) 371 (21.6) 288 (20.8) 144 (22.0) 27 (27.0) 22 (22.4) 5 (highest income quintile) 1028 (20.2) 357 (20.8) 290 (20.9) 126 (19.2) 17 (17.0) 26 (26.5) Unknown 25 (0.5) <6 <6 <6 <6 <6
10 Table e-2 Characteristics of the multiple sclerosis study population at the index date by subsequent disease-modifying treatment exposure (continued) Characteristics Unexposed 1 DMT Any betainterferon Glatiramer acetate Natalizumab Any oral DMT 1 st and 2 nd 1 st generation 1 st generation 2 nd generation 2 nd generation generation combined N=5077 N=1716 N=1386 N=656 N=100 N=98 Diabetes 310 (6.1) 54 (3.1) 46 (3.3) 26 (4.0) <6 <6 Malignancies 408 (8.0) 67 (3.9) 54 (3.9) 26 (4.0) <6 <6 Chronic lung diseases 497 (9.8) 131 (7.6) 106 (7.6) 59 (9.0) 7 (7) <6 Inflammatory bowel disease 56 (1.1) 16 (0.9) 10 (0.7) 7 (1.1) <6 <6 Rheumatoid arthritis 140 (2.8) 20 (1.2) 16 (1.2) 8 (1.2) <6 <6 Psoriasis 15 (0.3) 7 (0.4) 7 (0.5) <6 <6 <6 Number of comorbidities, N (%) None 3857 (76.0) 1449 (84.4) 1170 (84.4) 542 (82.6) 84 (84.0) 89 (90.8) (20.4) 242 (14.1) 195 (14.1) 99 (15.1) 16 (16.0) 9 (9.2) 2 or more 185 (3.6) 25 (1.5) 21 (1.5) 15 (2.3) 0 0 The oral DMTs included fingolimod and dimethyl fumarate. No person filled a prescription for teriflunomide, alemtuzumab, or the generic beta-interferon-1b (extavia ) during the study period. As some persons filled a prescription for more than one DMT during the study period, the sum of the subgroups exceeds the total number of people ever exposed (n=1716). Comorbidities identified during the 5 years prior to index date (diabetes, malignancies, chronic lung disease, inflammatory bowel disease, rheumatoid arthritis and psoriasis); all were included to generate the number of comorbidities. Due to privacy regulations, and as required by the data custodians (stewards), cells with less than 6 cases were not be reported.
11 Table e-3 Adjusted hazard ratios of physician claims for specific infections by multiple sclerosis disease modifying treatment Infection Model DMT exposure status Infection-related physician claims Person-years Crude rate per 1000 PY (95%CI) ahr (95%CI) Unexposed , ( ) reference 1 Any DMT ( ) 0.96 ( ) 2 Any 1 st generation DMT ( ) 0.94 ( ) 2 Any 2 nd generation DMT ( ) 1.58 ( ) Upper respiratory 3 Beta-interferon ( ) 0.92 ( ) tract infection 3 Glatiramer acetate ( ) 1.00 ( ) 3 Natalizumab ( ) 1.77 ( ) Any 1 st generation DMT ( ) reference 2 Any 2 nd generation DMT ( ) 1.68 ( ) Unexposed ( ) reference 1 Any DMT ( ) 1.09 ( ) 2 Any 1 st generation DMT ( ) 1.09 ( ) 2 Any 2 nd generation DMT ( ) 1.14 ( ) Infections of the 3 Beta-interferon ( ) 1.06 ( ) urinary system 3 Glatiramer acetate ( ) 1.16 ( ) 3 Natalizumab ( ) 1.21 ( ) Any 1 st generation DMT ( ) reference 2 Any 2 nd generation DMT ( ) 1.05 ( )
12 Table e-3 Adjusted hazard ratios of physician claims for specific infections by multiple sclerosis disease modifying treatment (continued) Infection Model DMT exposure status Infection-related physician claims Person-years Crude rate per 1000 PY (95%CI) ahr (95%CI) Unexposed ( ) reference 1 Any DMT ( ) 1.03 ( ) 2 Any 1 st generation DMT ( ) 1.03 ( ) Infections of the 2 Any 2 nd generation DMT ( ) 1.04 ( ) skin and 3 Beta-interferon ( ) 1.09 ( ) subcutaneous 3 Glatiramer acetate ( ) 0.85 ( ) tissue 3 Natalizumab ( ) 0.92 ( ) Any 1 st generation DMT ( ) reference 2 Any 2 nd generation DMT ( ) 1.01 ( ) Unexposed ( ) reference 1 Any DMT ( ) 0.93 ( ) 2 Any 1 st generation DMT ( ) 0.91 ( ) 2 Any 2 nd generation DMT ( ) 1.38 ( ) Bronchitis and 3 Beta-interferon ( ) 0.92 ( ) bronchiolitis 3 Glatiramer acetate ( ) 0.89 ( ) 3 Natalizumab ( ) 1.45 ( ) Any 1 st generation DMT ( ) reference 2 Any 2 nd generation DMT ( ) 1.52 ( )
13 Table e-3 Adjusted hazard ratios of physician claims for specific infections by multiple sclerosis disease modifying treatment (continued) Infection Model DMT exposure status Infection-related Pneumonia physician claims Person-years Crude rate per 1000 PY (95%CI) ahr (95%CI) Unexposed ( ) Reference 1 Any DMT ( ) 0.75 ( ) 2 Any 1 st generation DMT ( ) 0.72 ( ) 2 Any 2 nd generation DMT ( ) 1.66 ( ) 3 Beta-interferon ( ) 0.74 ( ) 3 Glatiramer acetate ( ) 0.64 ( ) 3 Natalizumab < ( ) Any 1st generation DMT ( ) Reference 2 Any 2 nd generation DMT ( ) 2.33( ) Key: ahr=adjusted Hazard Ratio; CI= Confidence Interval; DMT= disease modifying treatment; PY=person -years. Models were adjusted for sex, age (continuous), index year (continuous), SES (quintiles), number of comorbidities (none, 1, 2). Due to privacy regulations, and as required by the data custodians (stewards), cells with less than 6 cases were not be reported, nor were the corresponding crude rates. Oral DMTs were assessed only as part of the second generation drugs, i.e not as a separate class, due to the limited number of eve nts.
14 Table e-4 Adjusted hazard ratios of infection-related physician claims by multiple sclerosis disease modifying treatment stratified by sex and age at the index date Stratified by sex and age Men Women Age 44 Age 45+ Men Women Age 44 Age 45+ Model DMT exposure status Infection-related physician claims Person-years Crude rate per 1000 PY (95%CI) ahr (95%CI) Unexposed 6,724 12, ( ) reference 1 Any DMT ( ) 0.91 ( ) Unexposed 27,225 37, ( ) reference 1 Any DMT 3, ( ) 1.00 ( ) Unexposed 17,479 2, ( ) reference 1 Any DMT ( ) 0.99 ( ) Unexposed 16,470 2, ( ) reference 1 Any DMT ( ) 0.92 ( ) Unexposed 6,724 12, ( ) reference 2 Any 1 st generation DMT ( ) 0.86 ( ) Unexposed 27,225 37, ( ) reference 2 Any 1 st generation DMT ( ) 0.99 ( ) Unexposed 17,479 2, ( ) reference 2 Any 1 st generation DMT ( ) 0.97 ( ) Unexposed 16,470 2, ( ) reference 2 Any 1 st generation DMT ( ) 0.92 ( )
15 Table e-4 Adjusted hazard ratios of infection-related physician claims by multiple sclerosis disease modifying treatment stratified by sex and age at the index date (continued) Stratified by sex and age Men Women Age 44 Age 45+ Men Women Age 44 Age 45+ Model DMT exposure status Infection-related physician claims Person-years Crude rate per 1000 PY (95%CI) ahr (95%CI) Unexposed 6,724 12, ( ) reference 2 Any 2 nd generation DMT ( ) 2.09 ( ) Unexposed 27,225 37, ( ) Reference 2 Any 2 nd generation DMT ( ) 1.32 ( ) Unexposed 17,479 2, ( ) Reference 2 Any 2 nd generation DMT ( ) 1.52 ( ) Unexposed 16,470 2, ( ) Reference 2 Any 2 nd generation DMT ( ) 1.25 ( ) Unexposed 6,724 12, ( ) reference 3 Beta-interferon ( ) 0.81 ( ) Unexposed 27,225 37, ( ) reference 3 Beta-interferon ( ) 0.97 ( ) Unexposed 17,479 2, ( ) reference 3 Beta-interferon ( ) 0.95 ( ) Unexposed 16,470 2, ( ) reference 3 Beta-interferon ( ) 0.88 ( )
16 Table e-4 Adjusted hazard ratios of infection-related physician claims by multiple sclerosis disease modifying treatment stratified by sex and age at the index date (continued) Stratified by sex and age Men Women Age 44 Age 45+ Men Women Age 44 Age 45+ Model DMT exposure status Infection-related physician claims Person-years Crude rate per 1000 PY (95%CI) ahr (95%CI) Unexposed 6,724 12, ( ) reference 3 Glatiramer acetate ( ) 0.99 ( ) Unexposed 27,225 37, ( ) reference 3 Glatiramer acetate ( ) 1.07 ( ) Unexposed 17,479 2, ( ) reference 3 Glatiramer acetate ( ) 1.03 ( ) Unexposed 16,470 2, ( ) reference 3 Glatiramer acetate ( ) 1.07 ( ) Unexposed 6,724 12, ( ) Reference 3 Natalizumab ( ) 2.17 ( ) Unexposed 27,225 37, ( ) reference 3 Natalizumab ( ) 1.41 ( ) Unexposed 17,479 2, ( ) reference 3 Natalizumab ( ) 1.63 ( ) Unexposed 16,470 2, ( ) reference 3 Natalizumab ( ) 1.48 ( )
17 Table e-4 Adjusted hazard ratios of infection-related physician claims by multiple sclerosis disease modifying treatment stratified by sex and age at the index date (continued) Stratified by sex and age Men Women Age 44 Age 45+ Model DMT exposure status Infection-related physician claims Person-years Crude rate per 1000 PY (95%CI) ahr (95%CI) Any 1 st generation DMT ( ) reference 2 Any 2 nd generation DMT ( ) 2.42 ( ) Any 1 st generation DMT ( ) reference 2 Any 2 nd generation DMT ( ) 1.32 ( ) Any 1 st generation DMT ( ) reference 2 Any 2 nd generation DMT ( ) 1.57 ( ) Any 1 st generation DMT ( ) reference 2 Any 2 nd generation DMT ( ) 1.36 ( ) Key: ahr=adjusted Hazard Ratio; CI= Confidence Interval; DMT= disease modifying treatment; PY= person -years. Models were adjusted for sex (except for the sex-specific models), age (continuous, except for the age-specific models), index year (continuous), SES (quintiles), and number of comorbidities (none, 1, 2). Due to privacy regulations, and as required by the data custodians (stewards), cells with less than 6 cases were not be reported, nor were the corresponding crude rates. Oral DMTs were assessed only as part of the second generation drugs, i.e not as a separate class, due to the limited number of events.
ACHA Clinical Benchmarking Program
Acute Care Measure: Avoidance of Antibiotic Treatment for Adults Aged 18-64 with Acute Bronchitis Background The American College of Chest Physicians defines acute bronchitis as "an acute respiratory infection
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationQuality measures a for measurement year 2016
Quality measures a for measurement year 2016 Measure Description Eligible members Childhood immunizations b Adolescent immunizations b Children who turned 2 during the measurement and who were identified
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL efigures efigure: Standardised differences between TNF-α inhibitor users and non-users before and after matching on fixed factors and propensity scores. etables etable 1: All diagnoses
More informationAPPENDIX D SASKATCHEWAN MS DRUGS PROGRAM
APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM PROCEDURE FOR OBTAINING COVERAGE OF MS DRUGS UNDER THE DRUG PLAN Requests are initiated by a physician. The patient and physician complete the application form
More informationMellen Center Approach: MS and vaccination.
Mellen Center Approach: MS and vaccination. Q: Do vaccinations cause MS? A: Best evidence at present from numerous case control studies does not support a link between any vaccination and causation of
More informationTABLE C-1 RESIDENT DEATHS, LIVE BIRTHS, FETAL, INFANT, NEONATAL, AND MATERNAL DEATHS: PENNSYLVANIA,
TABLE C-1 RESIDENT DEATHS, LIVE BIRTHS, FETAL, INFANT, NEONATAL, AND MATERNAL DEATHS: PENNSYLVANIA, 1950-1997 - TOTAL LIVE FETAL INFANT NEONATAL MATERNAL DEATHS BIRTHS DEATHS DEATHS DEATHS DEATHS ----------------------------------------------------------------------------------
More informationSupplementary Online Content
Supplementary Online Content Lee C-C, Lee M-tG, Chen Y-S. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Internal Medicine. Published online October 5, 2015.
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationAppendix 2 (as supplied by the authors): ICD codes to identify high-risk children
Appendix 2 (as supplied by the authors): ICD codes to identify high-risk children ICD-9 codes to identify high risk children in physician claims database Category of condition Condition ICD-9 code Bacterial
More informationChapter 1: Certain Infectious and parasitic diseases (A00-B99)
ICD-10-CM Part 5 Chapter 1: Certain Infectious and parasitic diseases (A00-B99) New sub-chapter: Infections with a predominantly sexual mode of transmission (A50-A64) You will not find: septicemia - rather,
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationSupplementary materials for:
Supplementary materials for: Cecil E, Bottle A, Sharland M, Saxena S. Impact of UK primary care policy reforms on short-stay unplanned hospital admissions for children with primary care-sensitive conditions.
More informationGOALS AND OBJECTIVES INFECTIOUS DISEASE
GOALS AND OBJECTIVES INFECTIOUS DISEASE Infectious Disease and HIV Overview: The Infectious Diseases Program at the University of Southern California prepares trainees for the management of problems in
More informationLahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease
Lahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease Faculty representative: Eva Piessens, MD, MPH Resident representative: Karen Ganz, MD Revision date: February 1, 2006
More informationLeading Causes of Death, Tarrant County, 2008
Tarrant County Public Health Division of Epidemiology and Health Information Leading Causes of Death, Tarrant County, 00 Table 1. deaths by gender, Tarrant County, 00 Male,7. 70. Female,7 0.1 7. Total,7
More informationLeading Causes of Death, Tarrant County, 2007
Tarrant County Public Health Division of Epidemiology and Health Information Leading Causes of Death, Tarrant County, 007 Table 1. deaths by gender, Tarrant County, 007 Males,1 4. 70. Females,7 0. 741.
More informationLeading Causes of Death, Tarrant County, 2009
Tarrant County Public Health Division of Epidemiology and Health Information Leading Causes of Death, Tarrant County, 009 Table. deaths by gender, Tarrant County, 009 Male 5,5 9. 90. Female 5, 50. 70.
More informationProgress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada Today s Discussion Natural History and Classification of MS Treating MS Management
More informationA Glimpse at Immunomodulators in MS
A Glimpse at Immunomodulators in MS An Interview with Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC Multiple Sclerosis Research Unit, University of Ottowa, Ottowa Canada Ottawa Hospital Research Institute,
More informationINFECTIOUS DISEASES IN THE LONG TERM CARE FACILITY
INFECTIOUS DISEASES IN THE LONG TERM CARE FACILITY The following is a list of the most common infectious diseases that are to be found in the long term care facility. Precautions are recommended and the
More informationPediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More information0301 Anemia Others. Endocrine nutritional and metabolic disorders Others Vascular dementia and unspecified dementia
Certain infectious and parasitic diseases 0101 Intestinal infectious diseases 0102 Tuberculosis 0103 Infections with a predominantly sexual mode of transmission 0104 Viral infections characterized by skin
More informationTREATING MULTIPLE SCLEROSIS The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center
TREATING MULTIPLE SCLEROSIS 2018 The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center Welcome Thank you for joining us! Today you will learn about MS treatment choices
More informationAPPENDIX A. Comparability Ratios for the Major Causes of Death in North Carolina Vital Statistics, Volume 2
APPENDIX A Comparability Ratios for the Major Causes of Death in North Carolina Vital Statistics, Volume 2 The comparability ratio is an adjustment factor that is applied to the number of deaths coded
More informationSeema Sikka, MD January 18, 2014 TRANSVERSE MYELITIS: A CLINICAL OVERVIEW
Seema Sikka, MD January 18, 2014 TRANSVERSE MYELITIS: A CLINICAL OVERVIEW DISCLOSURES I have no industry relationships to disclose. I will not discuss off-label use. OBJECTIVES: TRANSVERSE MYELITIS Review
More informationClinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.CPA.334 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Novantrone) Reference Number: CP.CPA.334 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationPAEDIATRIC Point Prevalence Survey. Ward Form
Appendix 1 PAEDIATRIC Point Prevalence Survey Ward Form Please fill in one form for each ward included in PPS Date of survey Person completing form (Auditor code) Hospital Name Department/Ward Paediatric
More informationClinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.PHAR.258 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Novantrone) Reference Number: CP.PHAR.258 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
H.P. Acthar Gel (repository corticotropin) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: H.P. Acthar Gel (repository corticotropin) Prime Therapeutics
More informationWHAT ARE THE MOST COMMON CONDITIONS IN PRIMARY CARE?
WHAT ARE THE MOST COMMON CONDITIONS IN PRIMARY CARE? Finley C, Chan DS, Garrison S, Korownyk C, Kolber MR, Campbell S, Eurich D, Lindblad A, Vandermeer B, Allan GM. DISCLOSURE/COI Caitlin Finley, University
More informationPATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day
Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 6 PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Williams CM, Maher CG, Latimer J, et al. Efficacy
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective December 9, 2013 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationAttending Physician s Statement
( Form A A This form is used for claiming the social insurance benefit. This form should be completed and signed by the attending physician outpatient and One form for each month, one form for hospitalization
More informationInfluenza Situation Update
SUMMARY Influenza Situation Update 13 May 2014 http://www.wpro.who.int/emerging_diseases/influenza/en/index.html Northern Hemisphere In the Northern Hemisphere countries, influenza-like illness (ILI) activity
More informationFINAL. Etiologic Agents & Related Information to Know. Chapter 21: Microbial Diseases of Skin and Eyes Page No. Know term "diphtheroids"...
10 th Edition Tortora FINAL Microbiology Etiologic Agents & Related Information to Know Chapter 21: Microbial Diseases of Skin and Eyes Know term "diphtheroids"................. 586 Agents of boils and
More informationInfectious Diseases At A Glance in Durham Region
Infectious Diseases At A Glance in Durham Region Last Updated: November 2017 Highlights The rates of all reported infectious diseases combined are highest among youth and young adults aged 15 to 29 and
More informationAge-Specific Mortality Rate for All Infectious Diseases, Both Male & Female, Years
Per 100,000 population Health Indicators 10. Infectious Diseases 10-01. Infectious Disease Mortality Description Mortality Rate for all Infectious Diseases, by Age Group 400 Age-Specific Mortality Rate
More informationInfection Control Manual Residential Care Part 3 Infection Control Standards IC6: Additional Precautions
IC6: 0110 Appendix I Selection Table Infection Control Manual esidential Care IC6: Additional Legend: outine Practice * reportable to Public Health C - Contact ** reportable by Lab D - Droplet A - Airborne
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDo you or did you have any family members who have been diagnosed with MS? Yes No I Don t Know. Yes identical Yes not identical No
The following survey will ask you questions about your family history of MS, your MS diagnosis and history, your symptoms, and your treatments. You may find it easier to fully answer these questions if
More informationPremium Specialty: Pediatrics
Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium
More informationInfluenza Situation Update
SUMMARY Influenza Situation Update 10 June 2014 http://www.wpro.who.int/emerging_diseases/influenza/en/index.html Northern Hemisphere In the Northern Hemisphere countries, influenza-like illness (ILI)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationDiagnosis-specific morbidity - European shortlist
I Certain infectious and parasitic diseases 1 Tuberculosis A15-A19 X X Z 2 Sexually transmitted diseases (STD) A50-A64 Y Z 3 Viral hepatitis (incl. hepatitis B) B15-B19 X Z 4 Human immunodeficiency virus
More informationFlu adenovirus h1n1 h3n2 h5n1 ah1n1
Influenza influenza Flu adenovirus h1n1 h3n2 h5n1 ah1n1 Gastroenteritis Gastroenteritis stomach flu gastroenteritides gastroenterities food poisoning campylobacter colitis gastroenterocolitis gastrointestinal
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More informationInfluenza Situation Update
SUMMARY Influenza Situation Update 27 May 2014 http://www.wpro.who.int/emerging_diseases/influenza/en/index.html Northern Hemisphere Overall, in the Northern Hemisphere countries, influenza-like illness
More informationINDEX FOR 3 AND 4 DIGIT DIAGNOSTIC CODES (ICD9)
INDEX FOR 3 AND 4 DIGIT DIAGNOSTIC CODES (ICD9) INFECTIONS AND PARASITIC DISEASES 001-009.3 Intestinal and Infectious Diseases 010-018.9 Tuberculosis 020-027.9 Zoonotic Bacterial Diseases 030-041.9 Other
More informationMaking The Transition from ICD-9 to ICD-10 Coding Are You Ready?
Making The Transition from ICD-9 to ICD-10 Coding Are You Ready? Sherry Thomas, CCP, CCP-AS, CEO/Director of Education, Medical Staff SOS, Inc./PHIA, Louisville, KY Top 4 Things to Know for CE 1. Make
More informationInfluenza Situation Update
SUMMARY http://www.wpro.who.int/emerging_diseases/influenza/en/index.html Northern Hemisphere In the Northern Hemisphere countries, influenza-like illness (ILI) activity was variable. In Northern China,
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationBurden of acute respiratory infections across Western Australian emergency departments
Burden of acute respiratory infections across Western Australian emergency departments Rosanne Barnes, Chris C. Blyth, Nick de Klerk, Peter Richmond, Meredith Borland, Parveen Fathima, Faye J. Lim & Hannah
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationTENNCARE Bundled Payment Initiative: Description of Bundle Risk Adjustment for Wave 3 Episodes
TENNCARE Bundled Payment Initiative: Description of Bundle Risk Adjustment for Wave 3 Episodes Respiratory Infection (RI); Pneumonia (PNA); Inpatient Urinary Tract Infection (UTI-I; Outpatient Urinary
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAppendix 1. DATA SOURCES. A. Data on Recipients of Aid to Families with Dependent Children
Appendix 1. DATA SOURCES A. Data on Recipients of Aid to Families with Dependent Children The data on the characteristics of AFDC recipients come from two sources. The race share of adult and child recipients
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationCOPYRIGHT 2012 THE TRANSVERSE MYELITIS ASSOCIATION. ALL RIGHTS RESERVED
The Transverse Myelitis Association...advocating for those with acute disseminated encephalomyelitis, neuromyelitis optica, optic neuritis and transverse myelitis ACUTE DISSEMINATED ENCEPHALOMYELITIS (ADEM)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 11.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationMEDICATIONS USED TO TREAT UPPER RESPIRATORY TRACT INFECTION AND COMMON COLD
MEDICATIONS USED TO TREAT UPPER RESPIRATORY TRACT INFECTION AND COMMON COLD TABLE OF CONTENT OUR TPA MODEL FOR COMPREHENSIVE PBM SOLUTION PURPOSE OF THE DRUG UTILIZATION REVIEW (DUR) BACKGROUND ABOUT UPPER
More informationPharmacy Prep. Qualifying Pharmacy Review
Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use
More informationDisease-modifying therapies
Updated May 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. For some people, a diagnosis of multiple sclerosis (MS) is a relief, giving a name and a reason
More informationPrioritized ShortList MORBIDITY
Report on in-depth analysis of pilot studies in 16 Member States on diagnosis-specific morbidity statistics Annex 2 (Rev 11_11_13) Prioritized ShortList MORBIDITY Legend: X recommended for collection Y
More informationSupplementary Online Content
Supplementary Online Content Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-. JAMA. doi:10.1001/jama.2016.4151.
More informationCommunicable Disease. Introduction
Communicable Disease HIGHLIGHTS Seniors have the highest incidence rates of tuberculosis compared to other age groups. The incidence rates for TB have been higher among Peel seniors compared to Ontario
More informationUnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty
UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty 666700 Acne Family Medicine, Internal Medicine, Pediatrics 438300 Acute Bronchitis Allergy,
More informationenter the room. Persons immune from previous varicella infection may enter the room without a mask. Those immune by adenoviruses, influenza viruses.
All clients admitted to the hospital automatically are considered to be on standard precautions. The diseases listed below require standard precautions plus additional precautions that are noted in the
More informationCHILDHOOD IMMUNIZATIONS
CHILDHOOD IMMUNIZATIONS APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE What immunizations should be administered? NCQA ACCEPTED CODES DOCUMENTATION
More informationDISEASE-MODIFYING THERAPIES FOR MS
DISEASE-MODIFYING THERAPIES FOR MS Updated December 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. A multiple sclerosis (MS) diagnosis can bring a sense
More informationOrientation Program for Infection Control Professionals
Orientation Program for Infection Control Professionals Module 7: Communicable Diseases Table of Contents Module 7: Communicable Diseases... 1 Objectives... 1 Instructions... 1 Overview... 2 Key Concepts...
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationExclusion Periods for Infectious Diseases
Exclusion Periods for Infectious Diseases Amoebiasis (Entamoeba Histolytica) Campylobacter Candidiasis Chickenpox (Varicella) CMV (Cytomegalovirus Infection) Conjunctivitis Cryptosporidium Infection Diarrhoea
More informationInfectious Diseases Weekly Report. 12 January 2018 / Number 1. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 12 January / Number 1 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
More informationInfectious Diseases Weekly Report. 23 August 2018 / Number 33. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 23 August / Number 33 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
More informationInfectious Diseases Weekly Report. 8 November 2018 / Number 44. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 8 November / Number 44 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
More informationInfectious Diseases Weekly Report. 15 November 2018 / Number 45. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 15 November / Number 45 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
More informationInfectious Diseases Weekly Report. 14 March 2019 / Number 10. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 14 March / Number 10 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
More informationInfectious Diseases Weekly Report. 22 March 2019 / Number 11. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 22 March / Number 11 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
More informationInfectious Diseases Weekly Report. 28 March 2019 / Number 12. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 28 March / Number 12 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
More informationInfectious Diseases Weekly Report. 4 April 2019 / Number 13. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 4 April / Number 13 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
More informationInfectious Diseases Weekly Report. 11 April 2019 / Number 14. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 11 April / Number 14 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
More informationChoices. Disease modifying treatments. Read me
Choices Disease modifying treatments Read me Disease modifying treatments Disease modifying therapies (DMTs) are medications which modify the course of multiple sclerosis (MS) and are designed to reduce
More informationPage 1. Multiple Sclerosis. I have no conflicts of interest. Team Menstrual Cycles Waves to Wine for MS. Overview.
Multiple Sclerosis New Developments Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Team Menstrual
More informationIsle of Wight Joint Strategic Needs Assessment: Core Dataset 2009
Isle of Wight Joint Strategic Needs Assessment: Core Dataset 2009 Domain: Burden of Ill Health Indicator: Hospital Admissions - Top 10 Causes Sub-Domain: Misc Indicator References: JSNA Core Dataset number
More informationCreating a User Defined Pneumonia-Specific Syndrome in ESSENCE. Preventive Medicine Directorate September 2016
Creating a User Defined Pneumonia-Specific Syndrome in ESSENCE Preventive Medicine Directorate September 2016 0 Pneumonia-Specific Syndrome NMCPHC retrospective analyses suggest that surveillance using
More informationCircle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?
06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Tecfidera (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Ampyra (dalfampridine) Page 1 of 9 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Ampyra (dalfampridine) Prime Therapeutics will review Prior Authorization
More informationHUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING (Diagnosis)
HUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING (Diagnosis) NCD Source: Program Memorandum AB-02-110, Effective 11-25-02; Medicare NCD Manual, July 2003 Release; October 2003 Release; October 2004 Release;
More informationJ02.0 Streptococcal pharyngitis Yes No No 0 0 J03.00 Acute streptococcal tonsillitis, unspecified Yes No No 0 0
034.0 Streptococcal sore throat J02.0 Streptococcal pharyngitis J03.00 Acute streptococcal tonsillitis, unspecified J03.01 Description Acute recurrent streptococcal tonsillitis Use additional code to identify:
More informationMultiple Sclerosis , The Patient Education Institute, Inc. nr Last reviewed: 04/17/2017 1
Multiple Sclerosis Introduction Multiple sclerosis, or MS, is a disease of the brain and spinal cord. Most patients with multiple sclerosis are able to lead a very functional life. However, MS causes a
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Multiple Sclerosis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationTreatment Algorithm for Multiple Sclerosis Disease-modifying Therapies
Treatment Algorithm for Multiple Sclerosis Disease-modifying Therapies NHS England Reference: 170079ALG Date Published: 4 September 2018 Gateway reference: 07603 Treatment Algorithm for Multiple Sclerosis
More informationOptumInsight Learning: Detailed Instruction for Appropriate ICD-10-CM Coding
OptumInsight Learning: Detailed Instruction for Appropriate Coding An educational guide to the structure, conventions, and guidelines of coding Contents Chapter 1: Introduction...1 History of Modifications
More informationAnticipated Launches Q Q1 2019
Anticipated Launches Q4 2018-Q1 2019 Disease Prevalence Amyloidosis Tegsedi (inotersen) subcutaneous (SC) injection Akcea s/ionis Pharmaceuticals hereditary transthyretin amyloidosis (hattr) with polyneuropathy,
More informationWestern Pacific Regional Office of the World Health Organization.
Western Pacific Regional Office of the World Health Organization WPRO Influenza Situation Update, 19 November 2013 http://www.wpro.who.int/emerging_diseases/influenza/en/index.html SUMMARY Northern Hemisphere
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HNMC.CP.PHAR.259 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Medicaid Medi-Cal Coding Implications Revision Log See Important Reminder
More information